[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-melanoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100644407","classify-omm-multicenter-rare-disease-cohort-for-t-stage-reclassification-and-molecular-subtyping-based-precision-therapy-in-oral-mucosal-melanoma-100644407",false,"NCT07662694","CLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma","CLASSIFY-OMM","Inclusion Criteria:\n\n* Histopathologically confirmed primary oral mucosal melanoma (WHO criteria);\n\nPrimary site: oral mucosa (palate, gingiva, sublingual, buccal, hard palate, floor of mouth);\n\nReceiving or planning standard treatment (surgery, radiotherapy, chemotherapy, immunotherapy, or targeted therapy);\n\nAge ≥18 years, any sex;\n\nComplete clinical data with pathology, imaging, and records (retrospective) OR willingness for long-term follow-up (prospective);\n\nSigned informed consent (prospective) or data meeting ethical waiver (retrospective).\n\nExclusion Criteria:\n\n* Primary melanoma originating from skin, eye, esophagus, or other non-oral mucosal sites;\n\nSecondary\u002Fmetastatic oral mucosal melanoma (primary not in oral cavity);\n\nUnavailable key clinical information (surgical records, pathology, imaging);\n\nPrior or concurrent other malignancy interfering with prognosis;\n\nSevere mental\u002Fcognitive disorders or poor compliance;\n\nSevere comorbidities (heart failure, liver\u002Frenal failure) affecting treatment or survival analysis;\n\nPatient refusal or withdrawal of informed consent.","ALL","18 Years",{"count":19,"type":20},1100,"ESTIMATED","OBSERVATIONAL","This bidirectional cohort study (retrospective + prospective) focuses on three key challenges in oral mucosal melanoma (OMM): clinical staging based on depth of invasion (DOI), molecular subtyping, and precision therapy. By integrating DOI-driven T-stage reclassification, genomic profiling, and longitudinal follow-up, we aim to build a population-specific, high-quality evidence resource to support refined staging, CDK4-targeted treatment, and prognostic modeling for Chinese OMM patients.",[24,25],"Mucosal Melanoma of the Head and Neck","Oral Melanoma",[27],"Mucosal Melanoma","NOT_YET_RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-23","ACTUAL",{"date":34,"type":20},"2026-07-01",{"date":36,"type":20},"2029-12-30",{"name":38,"class":39},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER"]